Pfizer Stock: FDA Approves PADCEV Plus Keytruda for Early Bladder Cancer

What the FDA Approval Changed for PADCEV and Keytruda

The FDA approved Pfizer's PADCEV, an antibody drug conjugate, combined with Merck's Keytruda, for use before and after surgery in muscle invasive bladder cancer, known as MIBC. This is called neoadjuvant and adjuvant treatment, meaning patients get the drug combination both ahead of surgery to shrink the tumor and afterward to lower the chance it comes back. Until now, PADCEV plus Keytruda was mainly approved for bladder cancer that had already spread to other parts of the body. Moving the combination into earlier, potentially curable disease opens up a meaningfully larger pool of patients, since most bladder cancer is caught before it has spread widely.

Why Pfizer Stock Is in Focus

PADCEV came to Pfizer through its 2023 acquisition of Seagen, and it has become one of the more reliable growth drivers in Pfizer's oncology unit as older products like Paxlovid fade from view. An earlier stage approval extends the years a patient might realistically stay on therapy and adds a fresh, doctor facing label that oncologists can point to right after diagnosis, rather than waiting for the cancer to progress before considering the combination. For a company still working to convince investors its post pandemic pipeline can carry growth on its own, a label expansion into a much larger patient population is a concrete, quantifiable positive, even if the practical revenue benefit builds gradually as prescribing habits shift over time.

Which Stocks, and Why

Keytruda, made by Merck, is one of the best selling cancer drugs in the world, and this approval adds one more indication to an already long list of approved uses. The incremental impact on Merck's overall results is smaller than on Pfizer, simply because Keytruda already generates tens of billions of dollars a year across dozens of cancer types, so one more use case moves the needle less in relative terms. Still, every new approved combination extends Merck's exclusivity runway for the drug and reinforces its position as the default immunotherapy partner that other companies, including Pfizer, build their combination therapies around.

What to Watch

The practical test is how quickly urologists and oncologists start using the combination before surgery rather than the older standard of chemotherapy alone. Watch Pfizer's oncology segment revenue in coming quarters for PADCEV sales growth, and watch guidance from bodies like the National Comprehensive Cancer Network, since inclusion as a preferred regimen there often shifts prescribing patterns faster than the approval itself.